{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:06:47Z","timestamp":1791936407594,"version":"4.3.4"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ctrv.2025.103071","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:10:45Z","timestamp":1766074245000},"page":"103071","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["KELIM score: A marker of chemosensitivity in ovarian cancer"],"prefix":"10.1016","volume":"143","author":[{"given":"Federica Adele","family":"Ambrosino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Pisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena Di","family":"Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jole","family":"Ventriglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Tambaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Rossetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Passarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesta","family":"Cavalcanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella De","family":"Cecio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio Venanzio","family":"Setola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Troiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Lobianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Perri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariarosaria","family":"Lamia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Calvanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9631-5693","authenticated-orcid":false,"given":"Sandro","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina Chiara","family":"Cecere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ctrv.2025.103071_b0005","doi-asserted-by":"crossref","first-page":"47","DOI":"10.21037\/cco-20-34","article-title":"Epidemiology of ovarian cancer","volume":"9","author":"Gaona-Luviano","year":"2020","journal-title":"Chin Clin Oncol."},{"issue":"1","key":"10.1016\/j.ctrv.2025.103071_b0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13148-018-0602-0","article-title":"Epigenetic therapy for ovarian cancer: promise and progress","volume":"11","author":"Moufarrij","year":"2019","journal-title":"Clin Epigenetics."},{"issue":"4","key":"10.1016\/j.ctrv.2025.103071_b0015","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s11523-023-00970-w","article-title":"PARP Inhibitors in Ovarian Cancer: A Review","volume":"18","author":"O'Malley","year":"2023","journal-title":"Target Oncol."},{"key":"10.1016\/j.ctrv.2025.103071_b0020","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann Oncol."},{"issue":"13","key":"10.1016\/j.ctrv.2025.103071_b0025","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.7150\/jca.47695","article-title":"Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer","volume":"12","author":"Liu","year":"2021","journal-title":"J Cancer."},{"key":"10.1016\/j.ctrv.2025.103071_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102294","article-title":"The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas","volume":"100","author":"You","year":"2021","journal-title":"Cancer Treat Rev."},{"issue":"6","key":"10.1016\/j.ctrv.2025.103071_b0035","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.3390\/cancers15061823","article-title":"CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data","volume":"15","author":"Karamouza","year":"2023","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ctrv.2025.103071_b0040","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/jnci\/djh081","article-title":"Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)","volume":"96","author":"Rustin","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103071_b0045","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1136\/ijgc-2023-004825","article-title":"Prognostic value of CA125 kinetics, half-life, and nadir in the treatment of epithelial ovarian cancer: a systematic review and meta-analysis","volume":"33","author":"Kim","year":"2023","journal-title":"Int J Gynecol Cancer."},{"issue":"3","key":"10.1016\/j.ctrv.2025.103071_b0050","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41416-023-02528-z","article-title":"Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer","volume":"130","author":"Zebic","year":"2024","journal-title":"Br J Cancer."},{"issue":"2","key":"10.1016\/j.ctrv.2025.103071_b0055","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1470-2045(20)30591-X","article-title":"Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial","volume":"22","author":"Morgan","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctrv.2025.103071_b0060","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1245\/ASO.2006.08.021","article-title":"A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study","volume":"13","author":"Fagotti","year":"2006","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103071_b0065","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1136\/ijgc-2023-004540","article-title":"Change of Fagotti score is associated with outcome after neoadjuvant chemotherapy for ovarian cancer","volume":"33","author":"Saner","year":"2023","journal-title":"Int J Gynecol Cancer."},{"key":"10.1016\/j.ctrv.2025.103071_b0070","doi-asserted-by":"crossref","unstructured":"da Cunha Colombo Bonadio RR, Fogace RN, Miranda VC, Diz MDPE. Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management.Clinics (Sao Paulo). 2018;73(suppl 1):e450s. doi:10.6061\/clinics\/2018\/e450s.","DOI":"10.6061\/clinics\/2018\/e450s"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103071_b0075","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1200\/JCO.22.00430","article-title":"CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA\/GOG-3005 Study","volume":"41","author":"You","year":"2023","journal-title":"J Clin Oncol."},{"issue":"12","key":"10.1016\/j.ctrv.2025.103071_b0080","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1158\/2767-9764.CRC-24-0294","article-title":"Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer","volume":"4","author":"Kjeldsen","year":"2024","journal-title":"Cancer Res Commun."},{"issue":"3","key":"10.1016\/j.ctrv.2025.103071_b0085","doi-asserted-by":"crossref","first-page":"21","DOI":"10.21037\/cco-22-114","article-title":"Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis","volume":"12","author":"Batalini","year":"2023","journal-title":"Chin Clin Oncol."},{"issue":"10","key":"10.1016\/j.ctrv.2025.103071_b0090","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.annonc.2022.06.011","article-title":"Efficacy of subsequent chemotherapy for patients with BRCA1\/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2\/ENGOT Ov-21 trial","volume":"33","author":"Frenel","year":"2022","journal-title":"Ann Oncol."},{"issue":"3","key":"10.1016\/j.ctrv.2025.103071_b0095","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ygyno.2022.10.014","article-title":"Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer","volume":"167","author":"Piedimonte","year":"2022","journal-title":"Gynecol Oncol."},{"key":"10.1016\/j.ctrv.2025.103071_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104477","article-title":"Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10","volume":"89","author":"Colomban","year":"2023","journal-title":"EBioMedicine."},{"issue":"22","key":"10.1016\/j.ctrv.2025.103071_b0105","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","article-title":"Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma","volume":"33","author":"B\u00f6hm","year":"2015","journal-title":"J Clin Oncol."},{"issue":"4","key":"10.1016\/j.ctrv.2025.103071_b0110","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3390\/cancers13040704","article-title":"A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy","volume":"13","author":"Zhong","year":"2021","journal-title":"Cancers (Basel)."},{"issue":"3","key":"10.1016\/j.ctrv.2025.103071_b0115","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3390\/diagnostics12030633","article-title":"Prognostic Value of Chemotherapy Response Score (CRS) Assessed on the Adnexa in Ovarian High-Grade Serous Carcinoma: A Systematic Review and Meta-Analysis","volume":"12","author":"Santoro","year":"2022","journal-title":"Diagnostics (Basel)."},{"key":"10.1016\/j.ctrv.2025.103071_b0120","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.suronc.2020.03.001","article-title":"Pathologic chemotherapy response score in epithelial ovarian cancer: Surgical, genetic, and survival considerations","volume":"34","author":"Barrington","year":"2020","journal-title":"Surg Oncol."},{"issue":"1","key":"10.1016\/j.ctrv.2025.103071_b0125","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12943-022-01588-8","article-title":"Potential clinical utility of liquid biopsies in ovarian cancer","volume":"21","author":"Zhu","year":"2022","journal-title":"Mol Cancer."},{"issue":"13","key":"10.1016\/j.ctrv.2025.103071_b0130","article-title":"Liquid biopsy in ovarian cancer in China and the world: current status and future perspectives","volume":"19","author":"Zhang","year":"2023","journal-title":"Front Oncol."},{"issue":"9","key":"10.1016\/j.ctrv.2025.103071_b0135","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12032-023-02128-0","article-title":"Liquid biopsy in ovarian cancer: advantages and limitations for prognosis and diagnosis","volume":"40","author":"Karimi","year":"2023","journal-title":"Med Oncol."},{"issue":"7","key":"10.1016\/j.ctrv.2025.103071_b0140","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2217\/bmm-2022-0923","article-title":"KELIM score predicts outcome in patients with platinum-resistant\/refractory recurrent ovarian cancer","volume":"17","author":"Kus","year":"2023","journal-title":"Biomark Med."},{"issue":"1","key":"10.1016\/j.ctrv.2025.103071_b0145","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3390\/cancers14010098","article-title":"The Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative Review","volume":"14","author":"Lauby","year":"2021","journal-title":"Cancers (Basel)."},{"issue":"3","key":"10.1016\/j.ctrv.2025.103071_b0150","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.3802\/jgo.2024.35.e34","article-title":"Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a \u201creal-life setting\u201d","volume":"35","author":"van Wagensveld","year":"2024","journal-title":"J Gynecol Oncol."},{"key":"10.1016\/j.ctrv.2025.103071_b0155","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ygyno.2024.04.009","article-title":"Correlating the KELIM (CA125 elimination rate constant K) score and the chemo-response score as predictors of chemosensitivity in patients with advanced ovarian carcinoma","volume":"187","author":"Piedimonte","year":"2024","journal-title":"Gynecol Oncol."},{"issue":"2","key":"10.1016\/j.ctrv.2025.103071_b0160","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ygyno.2013.05.013","article-title":"The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study)","volume":"130","author":"You","year":"2013","journal-title":"Gynecol Oncol."},{"issue":"17","key":"10.1016\/j.ctrv.2025.103071_b0165","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-20-0054","article-title":"CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial","volume":"26","author":"You","year":"2020","journal-title":"Clin Cancer Res."},{"issue":"4","key":"10.1016\/j.ctrv.2025.103071_b0170","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1136\/ijgc-2023-004872","article-title":"Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients","volume":"34","author":"Bouvarel","year":"2024","journal-title":"Int J Gynecol Cancer."},{"issue":"1","key":"10.1016\/j.ctrv.2025.103071_b0175","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00005-022-00655-8","article-title":"Immunotherapy in Ovarian Cancer","volume":"70","author":"Siminiak","year":"2022","journal-title":"Arch Immunol Ther Exp (Warsz)."},{"key":"10.1016\/j.ctrv.2025.103071_b0180","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2009.27.4696","article-title":"Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer","volume":"28","author":"du Bois","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103071_b0185","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/jnci\/djj296","article-title":"Bois\u2008A, Wagner\u2008U, et al\u2008Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO","volume":"98","author":"Pfisterer","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2025.103071_b0190","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"issue":"34","key":"10.1016\/j.ctrv.2025.103071_b0195","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.22.01207","article-title":"Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study","volume":"40","author":"You","year":"2022","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ctrv.2025.103071_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112966","article-title":"Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis","volume":"191","author":"Corbaux","year":"2023","journal-title":"Eur J Cancer."},{"issue":"26","key":"10.1016\/j.ctrv.2025.103071_b0205","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ctrv.2025.103071_b0210","article-title":"Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7)","volume":"4(3):pkaa026","author":"Colomban","year":"2020","journal-title":"JNCI Cancer Spectr."},{"issue":"5\u20136","key":"10.1016\/j.ctrv.2025.103071_b0215","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1101\/gad.334516.119","article-title":"PARP and PARG inhibitors in cancer treatment","volume":"34","author":"Slade","year":"2020","journal-title":"Genes Dev."},{"issue":"1","key":"10.1016\/j.ctrv.2025.103071_b0220","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.ctrv.2025.103071_b0225","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ygyno.2017.08.022","article-title":"Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2","volume":"147","author":"Oza","year":"2017","journal-title":"Gynecol Oncol."},{"key":"10.1016\/j.ctrv.2025.103071_b0230","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT06660147?cond=Ovarian%20Cancer&term=PARP&aggFilters=status:rec&rank=7."},{"issue":"17","key":"10.1016\/j.ctrv.2025.103071_b0235","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ctrv.2025.103071_b0240","first-page":"A37","article-title":"562 Benefit from atezolizumab in patients with a poor prognostic ovarian cancer in first-line setting: IMAGYN-050 trial","volume":"34","author":"You","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ctrv.2025.103071_b0245","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS5626","article-title":"A pragmatic randomized phase III trial comparing the salvage weekly dose-dense regimen to the standard 3-weekly regimen in patients with poor prognostic ovarian cancers (GINECO-OV130b; ENGOT-ov78)","volume":"43","author":"You","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:58:00Z","timestamp":1770479880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225001938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":49,"alternative-id":["S0305737225001938"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103071","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KELIM score: A marker of chemosensitivity in ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103071"}}